A recent study published in the Journal of the American College of Nutrition (JACN) evaluated the absorption, cellular uptake and clinical effectiveness of MagSRTTM in a standard adult population.1 The authors reported that:

• MagSRTTM was well-tolerated by most individuals, with 91% of participants completing the 30-day trial. Individuals who continued the trial for 90 days, reported no side effects.
• Overall symptomatology, evaluated using a magnesium status questionnaire, improved 28% over 30 days and 63% over 90 days.
• Red blood cell (RBC) magnesium increased 6% and 30% over 30 and 90 days, respectively.
• 96% of all trial participants had baseline magnesium status within lab normal ranges; however, 79% and 89% had suboptimal serum and RBC magnesium status at baseline, respectively.